Novartis targets IgE-driven diseases with Excellergy buy, adding a phase I anti-IgE asset to boost its immunology pipeline and allergy franchise.

Novartis AG (NYSE:NVS) is one of the best immunotherapy stocks to buy according to hedge funds. Novartis AG (NYSE:NVS) announced on February 13 final results from the Phase III ALIGN study, stating ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With ...

Novartis AG faces major patent expiries but is buying pipeline assets to sustain growth. Click for this NVS update.

Candidates who have participated in the PRT Tier 2 exam can check the paper analysis here including difficulty level, pattern ...

KVS NVS Tier 2 Admit Card 2026: CBSE has released the admit cards for the Kendriya Vidyalaya Sangathan (KVS) and Navodaya ...

Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Novartis (NVS) and Novo Nordisk (NVO). But which of these two stocks is more attractive to value investors? We'll need ...